ALXO Stock Price, ALX Oncology Holdings . Quote, Chart

Market Summary

USD15.64-0.57

Market Closed

-3.52%

ALXO Alerts

1 major insider sales recently.

ALXO Stock Price

View Fullscreen

ALXO RSI Chart

ALXO Valuation

Market Cap

814.8M

Price/Earnings (Trailing)

-4.9

Price/Sales (Trailing)

735.22

EV/EBITDA

-5.12

Price/Free Cashflow

-5.77

ALXO Price/Sales (Trailing)

ALXO Profitability

EBT Margin

-13604.48%

Return on Equity

-101.22%

Return on Assets

-78.16%

Free Cashflow Yield

-17.33%

ALXO Fundamentals

ALXO Revenue

Revenue (TTM)

1.2M

ALXO Earnings

Earnings (TTM)

-166.2M

Earnings Growth (Yr)

-17.88%

Earnings Growth (Qtr)

21.75%

Breaking Down ALXO Revenue

Last 7 days

-0.9%

Last 30 days

20.0%

Last 90 days

10.5%

Trailing 12 Months

139.5%

How does ALXO drawdown profile look like?

ALXO Financial Health

Current Ratio

5.21

Debt/Equity

0.06

Debt/Cashflow

-14.48

ALXO Investor Care

Shares Dilution (1Y)

27.48%

Diluted EPS (TTM)

-3.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	4.4M	3.7M	2.4M	1.2M
2019	0	3.0M	3.9M	4.8M
2018	0	0	0	2.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ALX Oncology Holdings Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	pons jaume	sold	-318,334	15.9167	-20,000	president & cso
May 06, 2024	pons jaume	acquired	19,800	0.99	20,000	president & cso
Apr 16, 2024	pons jaume	acquired	25,587	0.99	25,846	president & cso
Apr 16, 2024	pons jaume	sold	-710,195	14.2039	-50,000	president & cso
Apr 04, 2024	pons jaume	sold	-223,036	11.1518	-20,000	president & cso
Mar 14, 2024	lettmann jason	bought	49,771	11.3117	4,400	chief executive officer
Feb 14, 2024	pinto shelly	acquired	-	-	15,000	svp, finance and cao
Feb 14, 2024	lettmann jason	acquired	-	-	60,000	chief executive officer
Feb 14, 2024	garcia peter s	acquired	-	-	25,000	chief financial officer
Feb 14, 2024	pons jaume	acquired	-	-	30,000	president & cso

Which funds bought or sold ALXO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	CITIGROUP INC	added	817	414,480	485,103	-%
May 10, 2024	PNC Financial Services Group, Inc.	unchanged	-	-490	1,461	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-11.95	-241,359	467,152	-%
May 10, 2024	Financial Advisory Group	unchanged	-	-117,499	350,300	0.06%
May 10, 2024	BlackRock Inc.	reduced	-0.61	-8,510,130	24,770,400	-%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-43.9	-708	513	-%
May 10, 2024	VANGUARD GROUP INC	added	4.26	-4,904,800	17,466,100	-%
May 10, 2024	CREDIT SUISSE AG/	new	-	175,780	175,780	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	reduced	-62.49	-1,438,030	561,303	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	12.39	-19,564	103,963	-%

Are Funds Buying or Selling ALXO?

Are funds buying ALXO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALXO

No. of Funds

ALXO Alerts

1 major insider sales recently.

Unveiling ALX Oncology Holdings Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	orbimed advisors llc	4.5%	2,255,000	SC 13G/A
Feb 14, 2024	redmile group, llc	9.6%	4,909,264	SC 13G/A
Feb 14, 2024	lsv associates, llc	2.7%	1,366,530	SC 13D/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Dec 20, 2023	lsv associates, llc	3.9%	1,950,004	SC 13D/A
Oct 16, 2023	redmile group, llc	9.6%	4,991,545	SC 13G
Oct 13, 2023	cormorant asset management, lp	5.28%	2,630,000	SC 13G
Feb 14, 2023	orbimed advisors llc	5.6%	2,266,000	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jun 10, 2022	wellington management group llp	2.77%	1,128,101	SC 13G/A

Recent SEC filings of ALX Oncology Holdings Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	144	Notice of Insider Sale Intent
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 08, 2024	4	Insider Trading
May 06, 2024	144	Notice of Insider Sale Intent
May 02, 2024	8-K	Current Report
May 02, 2024	DEFA14A	DEFA14A
Apr 23, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 18, 2024	4	Insider Trading

Peers (Alternatives to ALX Oncology Holdings Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

ALX Oncology Holdings Inc. News

Latest updates

ALX Oncology Holdings Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	-	-	-	1.00	1.00	1.00	1.00	1.00	-
Operating Expenses	81.7%	18.00	10.00	11.00	6.00	9.00	4.00	5.00	-
S&GA Expenses	26.8%	6.00	4.00	3.00	1.00	1.00	1.00	1.00	-
R&D Expenses	127.9%	12.00	5.00	8.00	4.00	7.00	2.00	4.00	-
Interest Expenses	23.4%	0.00	0.00	0.00	0.00	-	-	-	-
Income Taxes	420.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Earnings Before Taxes	-83.2%	-18.59	-10.15	-11.31	-5.45	-7.75	-3.04	-4.19	-
Net Income	-84.4%	-18.77	-10.18	-11.33	-5.45	-8.84	-4.11	-5.18	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-12.3%	213	243	220	246	278	306	318	346	364	380	400	421	433	436	262	103	57.00	11.00	11.00
Current Assets	-11.0%	168	189	199	220	233	271	291	317	322	367	389	412	432	436	262	101	-	10.00	10.00
Cash Equivalents	-37.0%	14.00	22.00	20.00	38.00	63.00	49.00	49.00	66.00	159	364	385	410	430	434	259	98.00	105	9.00	8.00
Net PPE	-4.1%	3.00	4.00	4.00	4.00	4.00	4.00	2.00	2.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	-	1.00	1.00
Liabilities	-8.3%	48.00	53.00	51.00	33.00	38.00	43.00	31.00	30.00	20.00	17.00	15.00	16.00	14.00	6.00	10.00	12.00	12.00	11.00	2.00
Current Liabilities	-10.5%	32.00	36.00	35.00	18.00	22.00	28.00	25.00	24.00	15.00	15.00	12.00	14.00	14.00	6.00	7.00	8.00	-	5.00	2.00
Long Term Debt	0.7%	10.00	10.00	10.00	10.00	9.00	9.00	-	-	-	-	-	-	-	-	3.00	4.00	-	5.00	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	2.00	-	-	-
LT Debt, Non Current	-100.0%	-	10.00	10.00	10.00	9.00	9.00	-	-	-	-	-	-	-	-	3.00	4.00	-	5.00	-
Shareholder's Equity	-13.5%	164	190	169	213	240	263	287	316	344	363	385	405	418	430	252	-	-	-	-
Retained Earnings	-7.3%	-521	-486	-440	-389	-355	-325	-294	-259	-226	-201	-173	-148	-132	-118	-99.75	-89.57	-	-72.78	-53.54
Additional Paid-In Capital	1.5%	686	676	610	603	596	590	583	577	571	565	559	554	551	548	352	5.00	-	2.00	2.00
Shares Outstanding	0.7%	50.00	50.00	41.00	41.00	41.00	41.00	41.00	41.00	41.00	40.00	40.00	40.00	-	-	-	-	-	-	-
Float	-	-	-	-	161	-	-	-	173	-	-	-	960	-	1,500	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	4.4%	-37,924	-39,678	-31,159	-31,711	-27,816	-20,668	-30,883	-16,998	-20,674	-17,488	-24,856	-20,622	-5,135	-13,615	-9,548	-6,163	-8,963	-2,874	-3,186	-	-
Share Based Compensation	4.6%	7,031	6,721	6,964	6,237	6,351	6,295	6,207	5,836	5,501	5,686	4,191	2,237	1,800	1,743	689	2,853	151	75.00	86.00	-	-
Cashflow From Investing	258.8%	26,473	-16,666	12,815	6,213	42,295	10,942	13,695	-76,132	-183,921	-4,518	-398	-	-7.00	-11.00	631	-	-10.00	62.00	-	-	-
Cashflow From Financing	-94.8%	3,086	59,166	-111	343	-107	9,494	-136	422	80.00	524	439	731	778	188,361	170,298	-769	104,991	5,927	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALXO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 31,717	$ 24,763
General and administrative	6,045	7,440
Total operating expenses	37,762	32,203
Loss from operations	(37,762)	(32,203)
Interest income	2,622	2,311
Interest expense	(427)	(387)
Other income (expense), net	(14)	95
Net loss	$ (35,581)	$ (30,184)
Net loss per share, basic	$ (0.71)	$ (0.74)
Net loss per share, diluted	$ (0.71)	$ (0.74)
Weighted-average shares of common stock used to compute net loss per share, basic	50,120,758	40,862,513
Weighted-average shares of common stock used to compute net loss per share, diluted	50,120,758	40,862,513

ALXO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 14,041	$ 22,406
Short-term investments	143,396	160,330
Prepaid expenses and other current assets	10,427	5,923
Total current assets	167,864	188,659
Property and equipment, net	3,441	3,589
Long-term investments	27,049	35,411
Other assets	14,296	14,894
Total assets	212,650	242,553
Current liabilities:
Accounts payable	6,227	8,591
Payable and accrued liabilities due to related party	$ 375	$ 543
Other Liability, Current, Related Party, Type [Extensible Enumeration]	us-gaap:RelatedPartyMember	us-gaap:RelatedPartyMember
Accrued expenses and other current liabilities	$ 25,626	$ 26,867
Total current liabilities	32,228	36,001
Term loan, non-current	9,703	9,639
Other non-current liabilities	6,524	7,201
Total liabilities	48,455	52,841
Commitments and contingencies (Note 11)
Stockholders’ equity
Common stock, $0.001 par value; 1,000,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 50,277,193 and 49,951,989 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	50	50
Additional paid-in capital	685,970	675,678
Accumulated other comprehensive loss	28	256
Accumulated deficit	(521,853)	(486,272)
Total stockholders’ equity	164,195	189,712
Total liabilities and stockholders’ equity	$ 212,650	$ 242,553

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

CEO	Mr. Jason W. Lettmann
WEBSITE	alxoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	72

ALX Oncology Holdings Inc. Frequently Asked Questions

What is the ticker symbol for ALX Oncology Holdings Inc.? What does ALXO stand for in stocks?

ALXO is the stock ticker symbol of ALX Oncology Holdings Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ALX Oncology Holdings Inc. (ALXO)?

As of Mon May 13 2024, market cap of ALX Oncology Holdings Inc. is 814.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALXO stock?

You can check ALXO's fair value in chart for subscribers.

What is the fair value of ALXO stock?

You can check ALXO's fair value in chart for subscribers. The fair value of ALX Oncology Holdings Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ALX Oncology Holdings Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALXO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ALX Oncology Holdings Inc. a good stock to buy?

The fair value guage provides a quick view whether ALXO is over valued or under valued. Whether ALX Oncology Holdings Inc. is cheap or expensive depends on the assumptions which impact ALX Oncology Holdings Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALXO.

What is ALX Oncology Holdings Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, ALXO's PE ratio (Price to Earnings) is -4.9 and Price to Sales (PS) ratio is 735.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALXO PE ratio will change depending on the future growth rate expectations of investors.